{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-022385","form_type":"8-K","ticker":"RLYB","cik":"0001739410","company_name":"Rallybio Corp","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.045946+00:00","generated_at":"2026-05-15T08:11:54.397415+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Rallybio CMO Steven Ryder departs immediately; severance tied to pending Candid merger","bullets":["Steven Ryder, M.D., Chief Medical Officer, leaves Rallybio effective March 31, 2026.","Severance includes payments for without-cause termination; additional contingent on Candid merger close.","Equity awards remain outstanding and vest per Merger Agreement; exercisable 90 days post-close.","Pending business combination with Candid Therapeutics announced March 1, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-022385","json":"https://secwatch.observer/filing/0001628280-26-022385.json","markdown":"https://secwatch.observer/filing/0001628280-26-022385.md","text":"https://secwatch.observer/filing/0001628280-26-022385.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739410/000162828026022385/0001628280-26-022385-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739410/000162828026022385/rlyb-20260331.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:11:54.397415+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}